RASAL2 functions as a tumor suppressor in a broad range of human tumors, including lung, ovarian, breast, and bladder cancer; low RASAL2 expression often correlates with aberrant Ras-ERK activation and worst prognosis [28,29]. Here, RASAL2 is linked to urinary bladder carcinoma.